LDR Holding Corporation is celebrating two major recent milestones. The company indicates that it has reached 80, 000 implantations of its exclusive VerteBRIDGE plating technology and 30, 000 implantations of its exclusive Mobi-C Cervical Disc replacement technology worldwide.
LDR Reaches Major Milestones

LDR President and CEO Christophe Lavigne told OTW, “It is very rewarding to see continued, positive and global growth in our two, primary platform technologies. We are very pleased to communicate on the latest implantation numbers, and as we look toward the future, LDR will remain focused on offering a portfolio of innovative and highly differentiated products.”
VerteBRIDGE was introduced in France in 2007 and debuted in the U.S. a year later. They are equipped with integrated, zero-profile, in-line plating technology adapted for use in anterior cervical, anterior lumbar, oblique lumbar, and lateral lumbar applications.
A company representative told OTW, “In addition, LDR’s exclusive Mobi-C Cervical Disc, the only FDA approved disc for both one and two-level use, is a mobile-bearing prosthesis specifically designed as a bone-sparing, cervical intervertebral disc replacement. LDR believes that Mobi-C offers a simplified surgical technique as compared to other, commercially available devices. Additionally, Mobi-C demonstrated superiority to anterior cervical discectomy and fusion in the two-level FDA study in overall trial success at 24 months.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.